What are the opening hours?

Monday 8am - 7pm Tuesday 8am - 6pm Wednesday 8am - 6pm Thursday 8am - 6pm Friday 8am - 6pm Saturday 8am - 6pm

Spakinect

Discover the simplicity of our virtual good faith evaluations for medical spas. SpaKinect is a physician-owned Medical Corporation.

Our practitioners are compassionate and knowledgeable with expertise in the field of TeleHealth Medicine. We aim to provide excellence in quality, service, and support. SpaKinect offers the most robust TeleHealth solution on the market with proven success in the wellness center industry. Whether you’re starting a new telehealth program, increasing the scope of your current program, or simply want

an effective, low-cost telemonitoring alternative, our Integrated Practitioner Services provide targeted, compassionate care that decreases wellness center costs and improves your patient’s visit. SpaKinect provides expert Telehealth practitioners that operate as a natural extension of your coordinated approval program. We serve as an integrated care team and combine the strengths of your local wellness center team with SpaKinect's centralized Telemedical expertise. The result is a highly effective, efficient, and scalable Telehealth program. SpaKinect can serve as your back-office, integrate your wellness approval protocols in our video conferencing and sophisticated electronic medical record software, and even generate approval letters in real time. By leveraging the latest breakthroughs in information technology, SpaKinect provides Telehealth and "cloud computing" systems with unparalleled advantages for wellness center medical professionals and clinicians. Our systems are designed to produce a digital standardized medical approval record that significantly reduces the cost of running medical wellness centers. Your clinic deserves knowledgeable and compassionate practitioners. From Start to Finish, your experience with SpaKinect will be simple, affordable and stress-free! SpaKinect's Telehealth practitioner experts can help you achieve your program outcome and ROI goals!

05/28/2026

🚨 A new California bill would impose $1,000-per-dose fines on unverified compounded GLP-1s, and bundles sourcing, testing, recordkeeping, and advertising rules into a single statute.

On May 18, 2026, the California State Assembly advanced AB 1990, the bill would create new requirements for certain compounded weight-loss drugs, including GLP-1 receptor agonists.

What AB 1990 would establish:
→ Sourcing standards requiring pharmaceutical-grade ingredients from FDA-registered, FDA-inspected manufacturers, with certificates of analysis on file
→ Quality-control testing before compounded GLP-1s are dispensed, with records retained for Board of Pharmacy review
→ Advertising disclosure rules, including FDA-approved active-ingredient risk information
→ Penalties of $1,000 per dose of illegally compounded drug, plus license revocation when applicable
The bill notably excludes licensed physicians and surgeons from its direct scope, targeting pharmacy-level compounders and the ingredient supply chain. Physicians remain subject to other applicable law.

AB 1990 sits inside a broader GLP-1 enforcement pattern. The FDA issued warning letters to 30 telehealth firms over compounded GLP-1 marketing in March 2026. Connecticut's Attorney General has settled cases tied to compounded GLP-1 advertising. California is now translating those concerns into statute.

California often sets the tone — other states tend to follow.

What Med Spa Owners should do now:
✔ Audit GLP-1 service pages and ads for claims that imply compounded equals FDA-approved
✔ Verify supplier files include sourcing, certificates of analysis, and testing documentation
✔ Maintain internal records of how compounded GLP-1 products are described and sourced
✔ Document the full prescribing and dispensing workflow

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/california-ab1990-compounded-glp1-sourcing-advertising

05/27/2026

Wondering whether you need a new "Patient-Specific Order process" on top of your Good Faith Exams?

Short answer: probably not. A compliant good faith exam already produces the documentation and clinical authorization that a patient-specific order requires — same standard, different name. The real issue is whether your current process can prove it.

Patient-specific orders are reshaping how Med Spa compliance is being discussed and marketed. Here's what the term actually means, how it compares to a good faith exam, and what every operator is asking right now.

💡 Read the full breakdown on our blog, reviewed for legal accuracy by attorneys at Lengea Law here: https://www.spakinect.com/blog/good-faith-exam-vs-patient-specific-order

05/26/2026

The FDA's biggest cosmetics oversight law in decades is in active implementation, and Med Spas with retail shelves should know where they stand.

The FDA released updated tools to help cosmetic facilities prepare for biennial registration renewal under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The framework covers facility registration, product listing, adverse event reporting, safety substantiation, records access, and mandatory recall authority.

For Med Spas, the key question is whether this applies to them.

The answer comes down to what's on your retail shelf. MoCRA reaches private-label skincare, branded retail products, and any practice involved in manufacturing or processing cosmetics. It does not reach injectables, lasers, peels, or IV therapy — those fall under separate drug and device rules.

But the broader signal matters. Private-label and branded skincare are one of the fastest-growing revenue lines in aesthetics, which means more practices land inside MoCRA's scope every year. This sits alongside FDA activity we've tracked on telehealth GLP-1 marketing and the RAPID device pathway — federal aesthetics oversight is broadening.

What to do now:
→ Inventory every cosmetic product sold through your practice
→ Identify the responsible person for each product
→ Verify private-label documentation covers listing, ingredients, and labeling
→ Maintain supplier records and adverse event routing

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/fda-mocra-registration-product-listing-cosmetics

05/22/2026

🚨 BREAKING: Alabama just became the first state in the country to formally prohibit the prescribing, administering, and dispensing of research-grade peptides.

On May 21, 2026, the Alabama Board of Medical Examiners and Alabama Medical Licensure Commission issued a joint notice making three things explicit:
→ Physicians must source all prescription products from Board of Pharmacy–permitted entities, and research-grade peptide vendors fall outside that system
→ Prescribing cannot be passed to CRNPs, CNMs, or PAs as a workaround
→ "Research-grade" patient waivers do not protect physicians from professional or legal liability

No other state has gone this far. Alabama is setting the precedent.

For Med Spas, the stakes are real:
→ Peptide therapy has become a core Med Spa revenue line
→ Delegation no longer creates a safe pathway
→ Liability follows the prescriber, regardless of what patients sign
→ Peptide compliance is a fast-moving regulatory area

Operators who get ahead of this now won't be scrambling when the next state moves.

What to do now:
✅ Audit every peptide currently on your service menu
✅ Verify each is FDA-approved and sourced from a permitted pharmacy
✅ Review any prescribing pathways delegated to NPs, PAs, or CNMs
✅ Retire "research-grade" consent forms as a liability shield

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

05/12/2026

New Jersey just expanded independent practice authority for certain APNs, but specifically excluded APNs providing elective aesthetic or cosmetic services.

On March 30, 2026, Governor Mikie Sherrill signed S2996/A4052, a law that permanently allows qualifying APNs in primary or behavioral health care to practice without a joint protocol with a collaborating physician. Med Spa APNs were watching this bill closely. The exclusion is deliberate — physician-collaboration requirements remain in place for elective aesthetic care.

Two APN tracks now exist in New Jersey:
→ Primary care APNs: Independent practice allowed (with 5,000+ hours and eligible specialty)
→ Aesthetic APNs: Cannot practice independently — joint protocol still required
The broader trend is consolidating — more states are treating Med Spa supervision as its own regulatory category

How NJ Med Spas stay ahead:
✔ Review APN collaboration agreements for elective aesthetic and cosmetic services
✔ Verify prescribing workflows for injectables, IV therapy, and wellness services
✔ Distinguish primary care from elective aesthetic models when structuring APN practice
✔ Audit medical director oversight and supervision workflows
✔ Document chart review and annual protocol activity to support compliance

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/new-jersey-s2996-excludes-elective-aesthetic-cosmetic-services-apn-exemption

05/11/2026

🚨 A Med Spa medical director is now facing felony homicide charges — including murder, manslaughter, and criminally negligent homicide.

On April 29 and 30, 2026, Texas prosecutors booked a former Med Spa owner and the practice’s former medical director on multiple felony charges tied to the July 2023 death of a patient who died following IV therapy treatment at a Med Spa in Wortham, Texas.

The case was the catalyst for Texas HB 3749, known as Jenifer’s Law — which we covered as it moved through the legislature in 2025. Now the underlying case has resulted in criminal charges against both the owner and the medical director.

What this case reveals for every Med Spa:
➡️ Medical director liability is real — being a medical director in name only is no longer just a regulatory issue
➡️ Supervision must be documented — TMB rules require active oversight, not signature-only relationships
➡️ IV therapy oversight is tightening — Jenifer’s Law established new statutory delegation rules effective Sept 1, 2025
➡️ Criminal liability extends beyond the owner — the entire compliance chain can be held accountable

How Texas Med Spas stay ahead:
✔️ Audit your IV therapy delegation chain
✔️ Document medical director involvement in protocols and training
✔️ Review IV protocols and emergency response plans
✔️ Confirm onsite coverage during IV therapy operations
✔️ Reassess credentialing and competency records for IV staff

Spakinect has been tracking Jenifer’s Law since 2025, and we’re here to help Texas Med Spas stay ahead of what comes next.
💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/texas-iv-therapy-death-jenifers-law-luxe-med-spa-charges

05/08/2026

Every nurse remembers the day they decided this was the path.

To our team, and to every nurse reading this, thank you for showing up, day after day, patient after patient.

Happy Nurses Week.

Tag a nurse who inspires you. 💜

05/06/2026

🚨 Amazon just entered the GLP-1 chat — joining a growing list of non-traditional providers, from fitness operators to retail giants.

On April 21, 2026, Amazon launched a GLP-1 Management Program through Amazon One Medical, combining primary care, telehealth, prescribing, monitoring, and pharmacy fulfillment in a single coordinated workflow. The program is available nationwide and includes structured screening, individualized treatment plans, ongoing monitoring, and same-day or next-day delivery through Amazon Pharmacy.

This reflects a broader shift in the GLP-1 industry across care delivery, patient access, and experience expectations.

How Med Spas can navigate the changing market:
✔️ Coordinate telehealth components that support your in-person care
✔️ Define your GLP-1 care pathway with screening, prescribing, follow-up, and monitoring
✔️ Align provider involvement with state law for prescribing and clinical decision-making
✔️ Maintain clinical documentation for every assessment, treatment plan, and visit
✔️ Document pharmacy workflows for how prescriptions are issued and fulfilled

Spakinect provides the foundation: Gold Standard telehealth-supported Good Faith Exams (GFEs) that help your Med Spa deliver coordinated, compliant GLP-1 care.

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/amazon-one-medical-glp1-program-telehealth-pharmacy-integration

05/05/2026

🚨 The FDA just made its first concrete move on peptide compounding restrictions in years.

On April 22, 2026, the FDA removed 12 peptides from Category 2 of its 503A bulk drug substances list — the list that flagged certain substances as ineligible for compounding due to safety or regulatory concerns.

Swipe to see which 12 peptides are affected.

Here’s what’s important to understand: the peptides weren’t pulled because of new safety findings. The original nominators withdrew their submissions, opening the door for these substances to be re-evaluated. The 2023 restrictions appear to be loosening, but these peptides are now in regulatory limbo, neither restricted nor approved for compounding.

What’s coming next:
➡️ The Pharmacy Compounding Advisory Committee (PCAC) is reviewing four of these substances (BPC-157, KPV, MOTs-C, TB-500) in July 2026
➡️ The remaining peptides are scheduled for review by February 2027
➡️ Final compounding eligibility depends on advisory committee recommendations and subsequent FDA action

What Med Spas should be doing now:
✔️ Verify peptide eligibility under section 503A before sourcing or compounding
✔️ Audit your compounding pharmacy partners for current 503A compliance
✔️ Capture prescriber documentation for every patient-specific prescription
✔️ Review your marketing language to align with FDA requirements
✔️ Prepare for patient questions: news coverage may prompt patients to ask about availability before anything has formally changed

Spakinect is tracking this story closely for Med Spas offering compounded peptide programs.

💡 Follow Spakinect for compliance insights designed specifically for Med Spa owners.

To read the full article, visit https://www.spakinect.com/news/fda-removes-12-peptides-503a-category-2-compounding

Address

5405 Morehouse Drive Suite 170
San Diego, CA
92121

Opening Hours

Monday	8am - 7pm
Tuesday	8am - 6pm
Wednesday	8am - 6pm
Thursday	8am - 6pm
Friday	8am - 6pm
Saturday	8am - 6pm

Telephone

+18772668455

Website

https://msha.ke/spakinect.com#links

Alerts

Be the first to know and let us send you an email when Spakinect posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.